Abstract
Background: Old patients have a poor prognosis when affected by ST elevation myocardial infarction (STEMI). The aim of our study was to evaluate the impact of age on acute and mid-term mortality in STEMI patients over one year in the pandemic period. Methods: we collected data on 283 STEMI patients divided into three groups according to age (not old, “Not-O”, ≤74 y/o; old, “O”, 75–84 y/o; very old, “Very-O”, ≥85 y/o). Results: the three groups did not differ in their clinical or procedural characteristics. The Very-O patients had a significantly increased incidence of in-hospital MACE (35%), mortality (30.0%), and percentage of cardiac death (25.0%). The only two independent predictors of in-hospital mortality were the ejection fraction (EF) [OR:0.902 (95% CI) 0.868–0.938; p < 0.0001] and COVID-19 infection [OR:3.177 (95% CI) 1.212–8.331; p = 0.019]. At follow-up (430 +/− days), the survival rates were decreased significatively among the age groups (Not-O 2.9% vs. O 14.8% vs. Very-O 28.6%; p < 0.0001), and the only two independent predictors of the follow-up mortality were the EF [OR:0.935 (95% CI) 0.891–0.982; p = 0.007] and age [OR:1.06 (95% CI) 1.018–1.110; p = 0.019]. Conclusions: in very old patients, all the accessory procedures that may be performed should be accurately and independently weighed up in terms of the risk–benefit balance and the real impact on the quality of life because of the poor mid-term prognosis.
Funder
Italian Ministry of Health, RCR 2021—Rete Cardiologica
Subject
Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献